The 275 kD hair-cell antigen (HCA) is a protein that was originally identified using immunological techniques in the inner ears of early hatchling and adult chickens. The HCA is specifically associated with the apical surface of sensory hair cells; in the vestibular system the antigen is distributed over the entire stereocilia bundle, but in the auditory system it only extends a short distance up the shafts of the stereocilia. The objectives of this study were to ascertain when the HCA is first expressed during inner ear development, to compare the temporal and spatial patterns of HCA expression with those of neurite ingrowth, and to determine how the distribution of the antigen observed in the auditory system arises during development. Serial sections of otocysts from embryonic day (ED) 4 to ED7.5 (stages 24 to 32) were stained with a monoclonal antibody to the HCA and polyclonal antibodies to the neuron-glial cell adhesion molecule in order to analyse patterns of HCA expression and neurite ingrowth. Nerve fibres are first observed in the anterior pole of the otocyst at ED4.5 (stage 24), and in the evaginating basilar papilla by ED5 (stage 26). The HCA first appears within the vestibular system in the anterior pole of the otocyst at ED5 (stage 26), and within the auditory system in the distal end of the basilar papilla at ED6.5 (stage 29). Serial section analysis indicates that expression of the HCA is always limited to areas of the epithelium where nerve fibres are found, although the delay between the onset of innervation and the onset of HCA expression varies from one region of the otocyst to another. The growth of stereocilia bundles in the auditory system was studied from ED10 to 2 days after hatching in sections from the medial to distal regions of the basilar papilla double labelled with rhodamine phalloidin and monoclonal anti-HCA. At ED12 the stereocilia bundles are 1.7 microns high and the staining observed with both phalloidin and the antibody extend to the same maximum height above the apical surface of the hair cell. The maximum height that anti-HCA staining extends up the stereocilia bundle remains almost constant between ED12 and postnatal day 2, but between ED15 and ED18 the stereocilia bundle grows rapidly in height, with a membrane domain lacking the HCA forming at the distal ends of the stereocilia.(ABSTRACT TRUNCATED AT 400 WORDS)

Spinal cord injury (SCI) induces a pronounced neuroinflammation driven by activation and proliferation of resident microglia as well as infiltrating peripheral monocyte-derived macrophages. Depending on the time post-lesion, positive and detrimental influences of microglia/macrophages on axonal regeneration had been reported after SCI, raising the issue whether their modulation may represent an attractive therapeutic strategy. Colony-stimulating factor 1 (CSF1) regulates microglia/macrophages proliferation, differentiation and survival thus, pharmacological treatments using CSF1 receptor (CSF1R) inhibitors had been used to ablate microglia. We analyzed the effect of chronic (10 weeks) food diet containing GW2580 (a CSF1R inhibitor) in mice that underwent lateral spinal cord hemisection (HS) at vertebral thoracic level 9. Treatment started 4 weeks prior to SCI and continued until 6 weeks post-lesion. We first demonstrate that GW2580 treatment did not modify microglial response in non-injured spinal cords. Conversely, a strong decrease in proliferating microglia was observed following SCI. Second, we showed that GW2580 treatment improved some parameters of motor recovery in injured animals through better paw placement. Using in and ex vivo magnetic resonance imaging (MRI), we then established that GW2580 treatment had no effect on lesion extension and volume. However, histological analyses revealed that GW2580-treated animals had reduced gliosis and microcavity formation following SCI. In conclusion, CSF1R blockade using GW2580 specifically inhibits SCI-induced microglia/macrophages proliferation, reduces gliosis and microcavity formations and improves fine motor recovery after incomplete SCI. Preventing microglial proliferation may offer therapeutic approach to limit neuroinflammation, promote tissue preservation and motor recovery following SCI.